Navigation Links
Double Helix Consulting Enhances its Strategic Product Commercialization Services with Appointment of Michael Rizzo as Vice President
Date:11/10/2009

NEW YORK, Nov. 10 /PRNewswire/ -- Double Helix Consulting US, a division of London-based Double Helix Development Group, today announced the appointment of Michael Rizzo to the position of Vice President. Rizzo joins a multidisciplinary team of highly experienced strategic pricing, reimbursement and market access consultants with extensive experience across the healthcare industry, which provides product commercialization services to firms in the pharmaceutical, biotechnology and medical device industries. DHC US provides services spanning the product lifecycle, including the following:

(Photo: http://www.newscom.com/cgi-bin/prnh/20091110/NY08977 )

(Logo: http://www.newscom.com/cgi-bin/prnh/20090330/NY91277LOGO )

  • Market opportunity assessment and entry strategy
  • New product planning
  • Product value message development and testing
  • Stakeholder influence mapping and engagement strategy
  • Managed markets strategy
  • Pricing and reimbursement research and planning
  • Mock formulary committee and reimbursement negotiation simulation
  • Health technology assessment and comparative effectiveness research preparation
  • Post-launch market access surveillance and lifecycle management

Drew Baker, President of Double Helix Consulting US, commented, "Mike complements our international market access, pricing and reimbursement capabilities through his vast experience in planning and implementing product development and launch strategies for the US market. His intimate knowledge of managed care market structure, formulary management, contracting strategies, and marketing communications strengthens Double Helix's ability to meet our clients' commercial objectives in the increasingly cost-conscious and value-driven US market."

Chief Executive Officer of Double Helix Development Group, Dr. Wayne Phillips, added, "Double Helix Consulting offers a premier set of services to assist our clients in optimizing product commercialization by enhancing market access through a truly global team of professionals with deep experience from industry, consulting, academia and healthcare authorities. As an example, we have assisted many of our clients with anticipating and generating the evidence needed to elucidate to payers the clinical and economic value associated with new medical technologies. Mike's experience in product planning and launch strategy bolsters our expanding capabilities."

Rizzo joins Double Helix Consulting from Campbell Alliance's managed markets practice where he led client engagements in stakeholder and access risk assessment, value proposition development and messaging, pricing and contracting strategy, product positioning, pull-through, and training. He brings extensive experience in assessing the impact of payers, physicians, patients, and intermediaries on pricing, access, and reimbursement for small molecule and specialty products in the US market. Rizzo's therapeutic expertise is broad including oncology, neurosciences, inflammatory disease, cardiometabolic disease, infectious disease, and women's health. He also worked with Charles River Associates' pharmaceuticals practice, the Pharmaceutical Research and Manufacturers Association (PhRMA), the Lombardi Cancer Research Center at Georgetown University, and The Institute for Genomic Research (TIGR). He holds an MBA from the College of William and Mary, a Master's of Public Policy from Georgetown University, and a BS in Biology from James Madison University.

    Contact:
    Andrew M. Baker
    President
    Double Helix Consulting US
    295 Madison Avenue, 12th Floor
    New York, NY 10017
    [T] 1.646.652.8506  [E] dbaker@dhelixc.com
    www.doublehelixdevelopment.com

Copyright © 2009 Double Helix Development US, Inc.

SOURCE Double Helix Consulting


'/>"/>
SOURCE Double Helix Consulting
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Harvest Technologies Announces Completion of Patient Enrollment in its Randomized, Controlled, Double Blind Multicenter IDE Non-Reconstructable Critical Limb Ischemia Trial
2. Chinas Research Output More Than Doubled Since 2004, Thomson Reuters Study Reveals
3. Global Biofuels Growth to Double by 2015
4. Aurora Biofuels Breakthrough Doubles CO2 Uptake and Fuel Production
5. Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses
6. Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products
7. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
8. Nanoparticles double their chances of getting into sticky situations
9. Carbon nanotube avalanche process nearly doubles current
10. SleepQuest Compliance Again Doubles Industry Average
11. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... OF PRUSSIA, Pa. , March 29, 2017 /PRNewswire/ ... to care, which is why CSL Behring awards Local ... work of rare disease patient groups. These groups tackle ... voices are heard on Capitol Hill and in statehouses ... funding cycle, the community-based grant was awarded to New ...
(Date:3/29/2017)... Germany , March 29, 2017 QIAGEN N.V. ... QIA) today announced the U.S. launch of its ipsogen ® ... by the U.S. Food and Drug Administration as a qualitative in vitro diagnostic ... from EDTA whole blood.* ... JAK2 assay is processed on QIAGEN,s Rotor-Gene ® Q MDx system, ...
(Date:3/29/2017)... SPRINGS, CO , March 29, 2017 /PRNewswire/ - Last year,s ... support kratom are not the only efforts active to generate awareness ... substitute opiate based pharmaceutical drugs in the healthcare market place. ... Earlier this month ... based developer and distributor of pharmaceutical and nutritional products, announced its ...
(Date:3/29/2017)... N.J. and PETACH TIKVAH, ...  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), ... technologies for neurodegenerative diseases, announced financial results ... "2016 was a highly successful ... important achievements and significant progress made on ...
Breaking Biology Technology:
(Date:3/24/2017)... Research and Markets has announced the addition ... Trends - Industry Forecast to 2025" report to their offering. ... The Global Biometric ... of around 15.1% over the next decade to reach approximately $1,580 ... market estimates and forecasts for all the given segments on global ...
(Date:3/22/2017)... March 21, 2017   Neurotechnology , a ... technologies, today announced the release of the ... provides improved facial recognition using up to 10 ... single computer. The new version uses deep neural-network-based ... and it utilizes a Graphing Processing Unit (GPU) ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel ... came to the DERMALOG stand together with the Japanese Prime Minster Shinzo ... At the largest German biometrics company the two government leaders could see ... as well as DERMALOG´s multi-biometrics system.   Continue ... ...
Breaking Biology News(10 mins):